Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis
Latest News
Tevogen Bio – September 14th, 2023
Tevogen Bio – July 12th, 2023
Tevogen Bio – June 29th, 2023
Tevogen Bio – May 11th, 2023
Tevogen Bio – April 26th, 2023
Tevogen Bio – January 23rd, 2023
Tevogen Bio – December 7th, 2022
Tevogen Bio – December 1st, 2022
Tevogen Bio – November 22nd, 2022
Tevogen Bio – October 27th, 2022
Tevogen Bio – October 12th, 2022
Warren-based biotechnology company Tevogen Bio, CEO nominated for 2023 Nobel Peace Prize
ROI-NJ – October 6th, 2022
Tevogen Bio – August 31st, 2022
Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors
Tevogen Bio – August 17th, 2022
Tevogen Bio – August 1st, 2022
Tevogen Bio – July 7th, 2022
Tevogen Bio – June 30th, 2022
Tevogen Bio – June 23rd, 2022
Ryan Saadi’s Commencement Speech at Washington University of Science and Technology
Tevogen Bio – June 21st, 2022
Tevogen Bio – June 7th, 2022
Tevogen Bio – May 3rd, 2022
Tevogen Bio – April 5th, 2022
Tevogen Bio – March 2nd, 2022
Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations
Tevogen Bio – February 7th, 2022
Tevogen Bio – February 3rd, 2022
SPH Dean’s next venture to drive down treatment costs
Yale Daily News – January 26th, 2022
Tevogen Bio – January 20th, 2022
Tevogen Bio – January 12th, 2022
Tevogen Bio – January 5th, 2022
Businesswire – December 29th, 2021
Businesswire – December 14th, 2021
Businesswire – December 8th, 2021
Businesswire – December 6th, 2021
SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19
Yale School of Public Health – December 6th, 2021
Businesswire – December 2nd, 2021
FDA OK’s next phase for Jefferson University’s new COVID-19 treatment
6ABC News – November 29th, 2021
SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced
Yale School of Public Health – November 22nd, 2021
Businesswire – November 16th, 2021
Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council
Businesswire – October 27th, 2021
A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System
Yale School of Public Health – October 8th, 2021
Businesswire – September 9th, 2021
Businesswire – September 1st, 2021
Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model
Pharma Tech Outlook – August 30th, 2021
Businesswire – July 14th, 2021
Businesswire – July 12th, 2021
Businesswire – May 11th, 2021
Businesswire – April 12th, 2021
Cell & Gene – March 23rd, 2021
Businesswire – March 15th, 2021
Newswire – January 25th, 2021
Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19
Newswire – October 14th, 2020
Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.
6ABC – August 20th, 2020
Newswire – August 10th, 2020
Newswire – July 15th, 2020
Tevogen Corporate Office – Warren, New Jersey



Presenting the Future Research and Manufacturing Facility of Tevogen Bio
Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly research and manufacturing facility to accommodate its anticipated growth. This planned facility will serve as the company’s central hub for research, manufacturing, and distribution. Congratulations to our team of visionary architects and lab engineers!











Social Media

© 2023 Tevogen Bio. All Rights Reserved.